Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent/Refractory B-cell Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06570447
What this trial is testing

Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL

Who this might be right for
Diffuse Large B-Cell Lymphoma-RecurrentDiffuse Large B-Cell Lymphoma-Refractory
Tianjin Medical University Cancer Institute and Hospital 22
Post-approval studies (Phase 4)Not Yet RecruitingNCT05814848
What this trial is testing

Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma

Who this might be right for
Relapsed or Refractory B-cell Lymphoma
Changhai Hospital 13
Early research (Phase 1)Not Yet RecruitingNCT06970496
What this trial is testing

A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.

Who this might be right for
Relapsed or Refractory B Cell Non Hodgkin Lymphoma
Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd. 48
Testing effectiveness (Phase 2)UnknownNCT04626908
What this trial is testing

Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma

Who this might be right for
Relapsed and RefractoryLymphoid Hematological Malignancies
He Huang 18
Testing effectiveness (Phase 2)Study completedNCT00052520
What this trial is testing

Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation

Who this might be right for
Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)+20 more
Fred Hutchinson Cancer Center 37
Testing effectiveness (Phase 2)Study completedNCT03128359
What this trial is testing

High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant

Who this might be right for
Acute LeukemiaChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaChronic Myelogenous Leukemia, BCR-ABL1 Positive+12 more
City of Hope Medical Center 38
Testing effectiveness (Phase 2)Study completedNCT01788189
What this trial is testing

Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell Lymphomas

Who this might be right for
B-cell Lymphoma
University Hospital, Essen 37
Testing effectiveness (Phase 2)Study completedNCT00980395
What this trial is testing

Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma

Who this might be right for
LymphomaMantle Cell LymphomaIndolent Lymphoma+1 more
University of Arizona 24
Early research (Phase 1)UnknownNCT02721407
What this trial is testing

Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients

Who this might be right for
Recurrent Adult Diffuse Large Cell LymphomaRecurrent Follicular LymphomaRecurrent Mantle Cell Lymphoma+3 more
Xinqiao Hospital of Chongqing 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT03162536
What this trial is testing

Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

Who this might be right for
Lymphoma, B-CellSmall Lymphocytic LymphomaChronic Lymphocytic Leukemia+6 more
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 190
Large-scale testing (Phase 3)Study completedNCT01805557
What this trial is testing

Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.

Who this might be right for
Diffuse Large B-cell Lymphoma RefractoryDiffuse Large B-cell Lymphoma Recurrent
Fondazione Italiana Linfomi - ETS 108
Testing effectiveness (Phase 2)Ended earlyNCT03572634
What this trial is testing

Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL

Who this might be right for
Chronic Lymphocytic LeukemiaCLLSLL+1 more
Sumitomo Pharma America, Inc. 3
Early research (Phase 1)Study completedNCT00005634
What this trial is testing

Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy

Who this might be right for
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+3 more
Memorial Sloan Kettering Cancer Center
Early research (Phase 1)Ended earlyNCT03103971
What this trial is testing

HuJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

Who this might be right for
Recurrent Adult Acute Lymphoblastic LeukemiaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell Lymphoma+14 more
Fred Hutchinson Cancer Center 55
Early research (Phase 1)Ended earlyNCT01088763
What this trial is testing

Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia

Who this might be right for
Childhood Atypical Teratoid/Rhabdoid TumorChildhood Central Nervous System ChoriocarcinomaChildhood Central Nervous System Germinoma+43 more
National Cancer Institute (NCI) 129
Testing effectiveness (Phase 2)WithdrawnNCT05936229
What this trial is testing

Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Who this might be right for
Recurrent B Acute Lymphoblastic LeukemiaRecurrent B-Cell Non-Hodgkin LymphomaRefractory B Acute Lymphoblastic Leukemia+3 more
Fred Hutchinson Cancer Center
Early research (Phase 1)Study completedNCT00114257
What this trial is testing

Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaMyelodysplastic Syndromes+1 more
National Cancer Institute (NCI) 36
Early research (Phase 1)WithdrawnNCT02532192
What this trial is testing

A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Who this might be right for
Lymphoma
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Study completedNCT00022581
What this trial is testing

Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Recurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular Lymphoma+1 more
National Cancer Institute (NCI) 45
Testing effectiveness (Phase 2)UnknownNCT00026429
What this trial is testing

Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma

Who this might be right for
LeukemiaLymphoma
Pharmatech Oncology
Next Page